Ying Du Sells 50,000 Shares of Zai Lab Limited (NASDAQ:ZLAB) Stock

Zai Lab Limited (NASDAQ:ZLAB) CEO Ying Du sold 50,000 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $32.44, for a total value of $1,622,000.00. Following the sale, the chief executive officer now owns 494,117 shares in the company, valued at approximately $16,029,155.48. This trade represents a 9.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Ying Du also recently made the following trade(s):

• On Friday, February 28th, Ying Du sold 50,000 shares of Zai Lab stock. The stock was sold at an average price of $34.47, for a total value of $1,723,500.00.

Zai Lab Price Performance

Shares of ZLAB stock opened at $35.91 on Thursday. The business’s 50 day simple moving average is $27.92 and its 200 day simple moving average is $26.18. Zai Lab Limited has a one year low of $13.48 and a one year high of $36.60. The stock has a market capitalization of $3.93 billion, a PE ratio of -12.96 and a beta of 1.02.

Zai Lab (NASDAQ:ZLAB) last announced its earnings results on Thursday, February 27th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.19). Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. The company had revenue of $109.07 million during the quarter, compared to the consensus estimate of $110.15 million. As a group, research analysts expect that Zai Lab Limited will post -2.58 earnings per share for the current year.

Institutional Trading of Zai Lab

Several institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC boosted its holdings in Zai Lab by 34.2% in the third quarter. Janus Henderson Group PLC now owns 8,760,074 shares of the company’s stock valued at $211,488,000 after acquiring an additional 2,232,507 shares during the last quarter. Wellington Management Group LLP lifted its stake in Zai Lab by 18.4% in the third quarter. Wellington Management Group LLP now owns 8,436,606 shares of the company’s stock valued at $203,660,000 after buying an additional 1,312,115 shares during the period. FMR LLC lifted its stake in Zai Lab by 749.1% in the fourth quarter. FMR LLC now owns 5,475,505 shares of the company’s stock valued at $143,403,000 after buying an additional 4,830,646 shares during the period. RTW Investments LP acquired a new position in Zai Lab in the fourth quarter valued at approximately $65,714,000. Finally, Price T Rowe Associates Inc. MD lifted its stake in Zai Lab by 30.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,354,025 shares of the company’s stock valued at $61,653,000 after buying an additional 548,378 shares during the period. 41.65% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ZLAB has been the topic of several research reports. Cantor Fitzgerald upgraded Zai Lab to a “strong-buy” rating in a report on Tuesday. Bank of America restated a “neutral” rating and set a $36.10 price target (up from $29.00) on shares of Zai Lab in a report on Monday.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.